August 15, 2017

Clinical Evaluation of IsoPSA, a Disease-Specific Biomarker for Prostate Cancer

Results show fewer unnecessary biopsies, enhanced prognostication


A novel prostate-specific antigen (PSA) assay could cut in half the number of unnecessary prostate biopsies, while simultaneously arming men and their doctors with improved prognostic information to guide treatment decisions, according to a clinical analysis of the new test.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The IsoPSA™ test, developed by Cleveland Clinic in collaboration with Cleveland Diagnostics, Inc.,* is a serum-based biomarker assay for prostate cancer that interrogates the entire spectrum of structural changes to PSA, which result from disordered cellular processes in prostate cancer.

“These are encouraging results from a testing platform we hope will better equip us with the information needed to find cancer early and treat it appropriately,” says Eric Klein, MD, Chairman of Cleveland Clinic Glickman Urological & Kidney Institute. “Accurate prognostication in prostate cancer is paramount to identifying appropriate treatment, and this test is another milestone in the development of biomarkers that could tell us how likely a cancer is to spread and whether intervention would be preferred over surveillance.”

PSA isoform testing capitalizes on structural changes to PSA that result from dysregulated cellular processes in prostate cancer, an improvement over existing PSA tests that are prostate-specific but not prostate-cancer specific.

According to a preliminary analysis published in European Urology, the new IsoPSA test outperformed standard PSA as both a cancer-no cancer test and a high-grade vs. low-grade test.

Study results

The European Urology study involved 261 men scheduled for prostate biopsy at five academic and community medical centers across the U.S. Overall, 53 percent of participating men were found to have some type of prostate cancer, and 34 percent had high-grade (Gleason ≥ 7) disease.

Result highlights:

  • IsoPSA outperformed standard PSA for both cancer detection and detection of high-grade disease
  • In detecting cancer, IsoPSA’s area-under-curve (AUC) was 0.79 (95% CI 0.73–0.84), vs. 0.61 (95% CI 0.54–0.67) for total PSA (p < 0.001)
  • For detecting high-grade cancer, IsoPSA’s AUC was 0.81 (95% CI 0.74–0.86), vs. 0.69 (95% CI 0.61–0.75) for total PSA (p < 0.005)

“By changing the focus from PSA concentration to PSA variants and structures, we have developed a testing paradigm that returns highly relevant information for providers and patients,” Dr. Klein maintains.

Until final validation is confirmed, IsoPSA is unavailable for routine use, but Dr. Klein is optimistic that ongoing evaluation of the test will lead to the conclusion that it provides superior detection and prognostication over current testing technologies, which include imaging and PSA testing.

Benefits of isoform testing

PSA testing is unique among molecular biomarkers in that it is specific to the gland being evaluated. The drawback is that it is tissue-specific, but not cancer-specific, and often leads to overtreatment and unnecessary biopsies.

In other words, many pathologies and biological processes unrelated to cancer (i.e. prostatitis, benign prostate hyperplasia and urinary tract infection) can elevate serum PSA levels.

IsoPSA, on the other hand, has been developed to evaluate structural changes in the PSA isoforms that correlate with prostate cancer. This approach not only reduces the number of false positives, it also allows providers a window into the cancer grade before deciding on whether a biopsy is indicated.

Benefits over traditional PSA testing include:

  • Agnostic to the presence or absence of specific PSA isoforms
  • Conditions including benign prostatic hyperplasia, inflammation and age have diminished effect on IsoPSA results
  • Measures all PSA isoforms without an a priori requirement of knowing which species are present, instead of just three or four prescribed antigen forms as measured by currently available tests

Series of firsts

IsoPSA represents the first potentially cancer-specific biomarker for prostate cancer detection and prognostication, Dr. Klein points out. Development of the assay has been ongoing for several years, and the most recent clinical test represents its world’s first clinical evaluation.

Most recently, the European Urology study demonstrated for the first time that use of a structure-based assay—rather than a concentration-based test—for the PSA has better diagnostic accuracy for detecting cancer and grade.

“Results of this study suggest that if validated and adopted clinically, IsoPSA could significantly reduce the number of unnecessary biopsies while preserving both positive and negative predictive values for cancer detection and staging,” says Dr. Klein. “This would be a major advancement in our ability to provide men with the information they need to make informed decisions about their care.”

*Cleveland Clinic has an equity position in Cleveland Diagnostics. Dr. Klein has no direct or indirect personal financial interests in the company.

Related Articles

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

January 30, 2024
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival

photo of Elekta Esprit Gamma Knife machine
January 26, 2024
The Evolution of Gamma Knife Technology (Podcast)

Improvements enable targeting of brain tumors with single-session, fractionated or neoadjuvant approaches

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Treating older patients with diffuse large B-cell lymphoma (DLBCL)
January 18, 2024
Trial for Patients 75 and Older with Diffuse Large B-Cell Lymphoma Helps Address Care Inequities

Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients